Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax Plus Zanubrutinib Compared With Venetoclax Plus Obinutuzumab in Previously Untreated CLL
NCT06073821Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2023
- Primary completion
- Feb 2032
- Modality
- Orthosteric Ligands
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of sonrotoclax in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by BeOne Medicines. Primary endpoints: Progression Free Survival and Rate of Undetectable Measurable Residual Disease. Started Nov 2023; status: active, not recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06073821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06073821.